Jeffrey Holt, PhD
Role
Founding member of the MISHA Scientific Advisory Board. Scientific authority on cochlear gene therapy and AAV vector design for inner-ear targets. SAB function: review of grant applications in the cochlear gene therapy and DFNB16-adjacent space; introductions; high-level scientific direction.
Background
Professor of Otolaryngology and Neurology at Harvard Medical School; principal investigator at Boston Children’s Hospital. One of the small number of labs that has translated cochlear gene therapy from rodent models toward human trials. Long collaborator with Yilai Shu (Fudan) on cochlear gene therapy programs.
Relationship history
- 2026-03-31 — verbal yes to join MISHA SAB
- 2026-04 — letter draft pending → index
Active commitments
- Sign SAB letter (1-page MISHA letterhead, term, scope, no-comp, expected ask cadence)
- Introduction path planning for Yilai Shu and US-based registry / gene-therapy contacts
Connections
[part-of]Board & Advisors[applies]index[applies]index[see-also]STRC Research Program